Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Lymphoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Hematological Malignancies (3919
)
Non-Hodgkin’s Lymphoma (1034
)
Hodgkin Lymphoma (60
)
Hematological Malignancies (3919
)
Non-Hodgkin’s Lymphoma (1034
)
Hodgkin Lymphoma (60
)
›
Associations
(1206)
News
Trials
Search handles
@ADesaiMD
@ARampotas
@AaronGoodman33
@Abdallah81MD
@AlGarfall
@AlhajMoustafa
@AnnaSureda5
@AshAlizadeh
@AuclairDan
@AyasunMDPhD
@BijoyTelivala
@BldCancerDoc
@CanerSaygin
@CathyEngMD
@CharuAggarwalMD
@ChenyuLinMD
@CwynKate
@CyclingDoctor
@DKirschMDPhD
@DahliaSano
@DanilovLab
@DavidSteensma
@Doc_Amarendra
@DrAEvens
@DrChoueiri
@DrChrisPFox
@DrDanPersky
@DrJFriedberg
@DrJonSchatzMD
@DrJulieVose
@DrLizBrem
@DrMCanales
@DrMMurphy
@DrMarcosdelima
@DrMiguelPerales
@DrNikitaMehra
@DrOlaLandgren
@DrRaulCordoba
@DrSGraff
@DrSapnaPatel
@DrSteveMartin
@Dr_Daniel_Molin
@Dr_Ivanoncologo
@Dr_RShatsky
@Dr_R_Kurzrock
@EduardoFlavioO1
@FAndreMD
@FasaAgbedia
@Fer_martinmoro
@GlopesMd
@GuiperiniMD
@HadidiSamer
@HayderSaeed_MD
@HemSandoval
@HenningWillers
@HiraseMD
@JanakiramMurali
@JohnPLeonardMD
@JuanAlderuccio
@Kwudhikarn
@LPopplew
@LeonidasPlatan1
@Lymphoma_Doc
@MCWardMD
@MDonatoBMT
@MKD_BMT
@ManniMD1
@MediHumdani
@Melanoma_doctor
@Mike_Oertel_MD
@MinnemaMonique
@Mohty_EBMT
@Myeloma_Doc
@NicoleKuderer
@NitinJainMD
@PGrivasMDPhD
@PLMcCarthyMD
@PatelOncology
@PatrickHwuMD
@Prasshmehta
@RShouval
@RabiHannaMD
@RahulBanerjeeMD
@RemyDulery
@RielyMD
@SCTNB
@SLentzsch
@ShannonWestin
@SimonLo21054188
@StefanoLuminari
@SyedMAhmedMDPhD
@TalhaBadarMD
@TaylorJ_MD
@ThiloZander
@Transplant_Doc
@UroDocAsh
@VanitaNoronha
@VincentRK
@VivekSubbiah
@ajumathew_
@akeithstewart
@albertomussetti
@aljurf100
@bdermanmd
@cancerassassin1
@chadinabhan
@chanyooncheah
@csgarrix
@davidhenrymd
@dawood_findakly
@dgermain21
@docbraunstein
@doctorpemm
@drjgauthier
@drkomanduri
@elizabeth_budde
@fdezdelarrea
@gioann72
@gloria_iacoboni
@graham74GC
@hematologo
@hemedoc
@iHematologo
@i_yakoub_agha
@ixazebe
@j_marquet
@jamecancerdoc
@jeff_sharman
@jrgralow
@kmody29
@majorajay
@manalipatelmd
@marklewismd
@michaelwangmd
@mike_dickinson1
@montypal
@mpdrc
@mshadman
@mtmdphd
@nlindenberg
@pashtoonkasi
@patrickreville
@pattymondello
@pebarba
@pnbarry
@rajuan_27
@rbryanbell
@samyamshon
@sejadiMD
@smbenlazar
@syed_abutalibmd
@szusmani
@timfenske
@tobyeyre82
@weldeiry
Search handles
@ADesaiMD
@ARampotas
@AaronGoodman33
@Abdallah81MD
@AlGarfall
@AlhajMoustafa
@AnnaSureda5
@AshAlizadeh
@AuclairDan
@AyasunMDPhD
@BijoyTelivala
@BldCancerDoc
@CanerSaygin
@CathyEngMD
@CharuAggarwalMD
@ChenyuLinMD
@CwynKate
@CyclingDoctor
@DKirschMDPhD
@DahliaSano
@DanilovLab
@DavidSteensma
@Doc_Amarendra
@DrAEvens
@DrChoueiri
@DrChrisPFox
@DrDanPersky
@DrJFriedberg
@DrJonSchatzMD
@DrJulieVose
@DrLizBrem
@DrMCanales
@DrMMurphy
@DrMarcosdelima
@DrMiguelPerales
@DrNikitaMehra
@DrOlaLandgren
@DrRaulCordoba
@DrSGraff
@DrSapnaPatel
@DrSteveMartin
@Dr_Daniel_Molin
@Dr_Ivanoncologo
@Dr_RShatsky
@Dr_R_Kurzrock
@EduardoFlavioO1
@FAndreMD
@FasaAgbedia
@Fer_martinmoro
@GlopesMd
@GuiperiniMD
@HadidiSamer
@HayderSaeed_MD
@HemSandoval
@HenningWillers
@HiraseMD
@JanakiramMurali
@JohnPLeonardMD
@JuanAlderuccio
@Kwudhikarn
@LPopplew
@LeonidasPlatan1
@Lymphoma_Doc
@MCWardMD
@MDonatoBMT
@MKD_BMT
@ManniMD1
@MediHumdani
@Melanoma_doctor
@Mike_Oertel_MD
@MinnemaMonique
@Mohty_EBMT
@Myeloma_Doc
@NicoleKuderer
@NitinJainMD
@PGrivasMDPhD
@PLMcCarthyMD
@PatelOncology
@PatrickHwuMD
@Prasshmehta
@RShouval
@RabiHannaMD
@RahulBanerjeeMD
@RemyDulery
@RielyMD
@SCTNB
@SLentzsch
@ShannonWestin
@SimonLo21054188
@StefanoLuminari
@SyedMAhmedMDPhD
@TalhaBadarMD
@TaylorJ_MD
@ThiloZander
@Transplant_Doc
@UroDocAsh
@VanitaNoronha
@VincentRK
@VivekSubbiah
@ajumathew_
@akeithstewart
@albertomussetti
@aljurf100
@bdermanmd
@cancerassassin1
@chadinabhan
@chanyooncheah
@csgarrix
@davidhenrymd
@dawood_findakly
@dgermain21
@docbraunstein
@doctorpemm
@drjgauthier
@drkomanduri
@elizabeth_budde
@fdezdelarrea
@gioann72
@gloria_iacoboni
@graham74GC
@hematologo
@hemedoc
@iHematologo
@i_yakoub_agha
@ixazebe
@j_marquet
@jamecancerdoc
@jeff_sharman
@jrgralow
@kmody29
@majorajay
@manalipatelmd
@marklewismd
@michaelwangmd
@mike_dickinson1
@montypal
@mpdrc
@mshadman
@mtmdphd
@nlindenberg
@pashtoonkasi
@patrickreville
@pattymondello
@pebarba
@pnbarry
@rajuan_27
@rbryanbell
@samyamshon
@sejadiMD
@smbenlazar
@syed_abutalibmd
@szusmani
@timfenske
@tobyeyre82
@weldeiry
Filter by
Latest
8ms
SCI member @AshAlizadeh & others provide the first direct evidence for the presence of genetic alterations in circulating precursor cells years before overt #FollicularLymphoma development, dominated by CREBBP mutations within the KAT domain. https://t.co/dHkXrUJKIQ #lymsm (@SCIDirector)
8 months ago
CREBBP (CREB binding protein)
|
CREBBP mutation
8ms
@DrKrinaPatel is multi talented, now running a session on lymphoma CAR-T and presented some promising data on CD70 allo CAR-T in T cell lymphoma. This target may be used in #mmsm in future Hard disease and 2 pts cases with early promising results @DAVAOnc #DAVABermudaHeme (@HadidiSamer)
8 months ago
Clinical
|
CD70 (CD70 Molecule)
8ms
🗣️:🇺🇲/👥: 👨⚕️🩸🦀 🤔 Peripheral flow cytometry for a possibility of firstly hairy cell leukemia and than marginal zone lymphoma. Bone marrow Asp&biopsy for BRAF mutation, and further differantiate possible causes. If one of them watch & wait might be a rational solution. (@Dr_MSU)
8 months ago
Biopsy
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
8ms
New manuscript published in @BloodAdvances validating the new "Severe4" comorbidity index to predict post-CAR-T outcomes in DLBCL, with our @CULymphoma faculty Drs. @StevenBairMD and @mana1981 contributing. #lymsm #celltherapy cc @DanilovLab https://t.co/yi58TtfUz5 (@CULymphoma)
8 months ago
8ms
Please sign up for this meeting in #radiotherapy for #lymphoma patients, #lymphsm @WomenInLymphoma @Dr_Daniel_Molin @LenaSpecht1 @glimelius (@glimelius)
8 months ago
Clinical
8ms
Introducing @MeeraMohanMD (@MedicalCollege): speaker at our 2023 Wisconsin Multiple Myeloma & Lymphoma Summit! We're excited for this session, make sure to attend August 26 in Milwaukee. ➡️LEARN MORE: https://t.co/EbFkMP5Kr8 #CME #Oncology #MultipleMyeloma #Lymphoma (@btfoundation)
8 months ago
CME
8ms
Is a new era dawning for ctDNA in lymphoma? In our latest feature, Alex Herrera, MD, and @SwethaKamMD of @cityofhope; @RoschewskiMD of @NCICCR_Lymphoma; and Margarita Sánchez-Beato, PhD, of @idiphisa_op, discuss what they see on the horizon. 📚: https://t.co/gR8s2Ms9HQ (@Blood_Cancers)
8 months ago
Circulating tumor DNA
8ms
Diagnosis of enteropathy-associated T-cell lymphoma (EATL) on peripheral blood: A pleiomorphic morphology and an unusual immunophenotype https://t.co/q4bYOKUrUq #EATL #lymsm @draevens (@e_JHaem)
8 months ago
8ms
yes, @eye4msu that is the trick- who is still at high risk so they get Paxlovid & boosters. My father is 88 s/p chemo for B cell lymphoma & did fine with COVID but we boosted & gave him Paxlovid - that is what I mean (@MonicaGandhi9)
8 months ago
8ms
A discussion with Matthew Matasar, MD, MS, on using loncastuximab tesirine and tafasitamab/lenalidomide in patients with relapsed/refractory diffuse large B-cell #lymphoma. #DLBCL #lymsm | @DrMatasar @RutgersCancer https://t.co/LKM8ZtGFIq (@TargetedOnc)
8 months ago
Clinical
|
lenalidomide • Zynlonta (loncastuximab tesirine-lpyl) • Monjuvi (tafasitamab-cxix)
8ms
2) .@tobyeyre82 discusses here more on #pharmacology, patient selection for #CAR_T, and sequencing of CAR T tx in the management of #CLL. Until recently, this approach was not as successful as it has been in #B_cell #leukemia and #lymphoma. (@onc_ce)
8 months ago
Clinical
8ms
22) And you just earned 0.5hr 🆓CE/#CME. Just go to https://t.co/3iW8CFZcQj and claim your certificate! Tracking rapid advances in the management of #pan_lymphoma is challenging. Let @tobyeyre82 and our other expert faculty help you keep up as we support our patients! (@onc_ce)
8 months ago
Clinical
8ms
💥📰💥📰💥 📰We are excited to share our first NNHLA Newsletter with you all! Be sure to take a look to find out more about our work. https://t.co/yo8GgTC9n7 @NATCAN_news @bloodcancer_uk @LymphomaAction @DavidJCutter @KateWalkerLon @AnthonyNolan @HQIP (@NNHLA_NATCAN)
8 months ago
8ms
The lymphomas are everywhere. Scary. But it's only one out of 12 cancerous problems spike and vaccine induces. SV40 promoter dsDNA contamination and TP53 suppression the biggest. Studies for everything, besides the tendency to reject vaccination negative information. (@SitSilver)
8 months ago
Clinical
|
TP53 (Tumor protein P53)
8ms
“The data are promising and may offer a clinical advantage as an off-the-shelf option compared with approved autologous CAR T cell therapies,” says our Dr. Loretta Nastoupil of results from the ANTLER Phase I trial. https://t.co/C4L7wOd28I @LNastoupilMD #lymphoma #EndCancer (@MDAndersonNews)
8 months ago
Clinical • CAR T-Cell Therapy
8ms
Suffering "Diffuse large B-cell lymphoma" ZEBA TAHSIN 16Y my daughter. advice to survive properly (@MdZahid1974)
8 months ago
8ms
@JudithTrotman1 @MinnemaMonique @c_thieblemont #KarimaAmaador @lymphomaOz #lymphoma #MZL #WM #WaldenströmsMacroglobulinemia (@WomenInLymphoma)
8 months ago
8ms
In a Review now published online, @JuanAlderuccio, Russ A. Kuker, Fei Yang and @CraigMoskMD @SylvesterCancer explain how PET-based biomarkers can be used to improve the management of patients with #lymphoma undergoing treatment https://t.co/93QbYoWOZb (@NatRevClinOncol)
8 months ago
Clinical • Review
8ms
Delighted to share our @NatRevClinOncol article on PET-biomarkers in #lymphoma https://t.co/SpEZW747ne We review the status of imaging biomarkers, radiomics, #AI, shortcomings, and how to deploy into risk-adapted clinical trials @SylvesterCancer @CraigMoskMD (@JuanAlderuccio)
8 months ago
Clinical • Review
8ms
Amazing work by our lymphoma team @SylvesterCancer an honor to work with each of you @JuanAlderuccio @CraigMoskMD can't wait to see what's next! (@DrTracyECrane)
8 months ago
9ms
In this episode of #OncLiveOnAir, @lymphomaphilia & Jeremy Abramson, MD, discuss treatment options for patients with LBCL following relapse on their initial therapies & challenges that arise in clinical trials vs in the real-world setting. #lymsm https://t.co/9EUlkybeQl (@OncLive)
9 months ago
Clinical • Real-world evidence • Real-world
9ms
Dr. @ravivij Discussing with @NehaMehtaShahMD on #pheripheral #tcell #lymphoma (PTCL) at @My_Cancer_Haven Thank You So much for your support @NehaMehtaShahMD 😊🙏 Get Full Access to the Video, by Signing Up at https://t.co/XIinFH8pLB https://t.co/nnm8ehgnlj (@My_Cancer_Haven)
9 months ago
Video
9ms
These two MD Anderson docs delivered the best news today to my hubbs. Continued remission! Who in the world cares more about mantle cell lymphoma? @michaelwangmd Charles Gaulin MD @MDAndersonNews #mantlecelllymphoma (@nanswa1)
9 months ago
Clinical
9ms
Angiosarcoma or primary cardiac lymphoma Mo? (@drrasch)
9 months ago
9ms
I know @majorajay did a similar project with myeloma in his youth – I think it would be an excellent idea to look into with lymphoma therapies as well! (@RahulBanerjeeMD)
9 months ago
9ms
📢 In this trial, pirtobrutinib showed efficacy in patients with heavily pretreated CLL or SLL who had received a covalent BTK inhibitor @NEJM Read➡️https://t.co/me8JOkT0VG #MedTwitter @Daver_Leukemia @LeukemiaRF @LLSResearch @LYM_MM_CONNECT @lymphomahub @Lymphoma_Doc (@bloodmeded)
9 months ago
Clinical
|
Jaypirca (pirtobrutinib)
9ms
Privileged to talk with Dr Jennifer Peterson about bridging #RT to CAR T-cell therapy for r/r aggressive #lymphoma. Novel work by @OmranSaifi et al @MayoClinic ➡️https://t.co/J8PhQW3Uty Huge 🙏 to @sueyom & @IJROBP for this excellent #RedJournal podcast. @ILROGTeam @PeterMacCC (@belinda_campbe)
9 months ago
CAR T-Cell Therapy
9ms
📣Hear the latest IACH Breaking News: CD19 CAR T-Cell Therapy and Prophylactic Anakinra in Relapsed or Refractory Lymphoma: Phase 2 Trial Interim Results by @drjgauthier ⬇️⬇️⬇️ https://t.co/JyY70TmFRr @nagler_EBMT @Mohty_EBMT (@TheIACH)
9 months ago
CAR T-Cell Therapy
|
Kineret (anakinra)
9ms
A multicentre analysis of ACOPP for older/less fit patients with Hodgkin lymphoma. Promising efficacy and deliverability providing an option for this challenging clinical scenario https://t.co/S0DaILQOeI @mattwilson2287 @pammckay123 @wendster #lymsm @DrAEvens @BritSocHaem (@BrJHaem)
9 months ago
Clinical
9ms
suffering NON HODGKIN LYMPHOMA, stage-4 (@MdZahid1974)
9 months ago
Metastases
9ms
Normally I would agree but I have seen some pretty bad quality of life from Aggressive lymphoma now cured after cart. It’s getting more challenging (@AaronGoodman33)
9 months ago
HEOR
9ms
Just make sure the names of the lymphomas line up with the pathology nomenclature and your lab friends will be happy. (@jrstumph)
9 months ago
9ms
Further research projects and Clinical Trials are needed to evaluate the safety and the efficacy of the CAR 7 T cells if would it be applicable on T cell lymphoma as if it is in T Cell ALL published in New England Journal of Medicine June 2023 (@Rashed_AlBakr)
9 months ago
Clinical
9ms
Can you do follicular lymphoma next? And also, can you plz wave a magic wand so that the USA guidelines are acknowledged and followed in Canada? Asking for a friend… (@MGregoryAuthor)
9 months ago
9ms
Lymphoma? (@PavelDusek)
9 months ago
9ms
In this episode of #OncLiveOnAir, @lymphomaphilia & Jeremy Abramson, MD, discuss treatment options for patients with LBCL following relapse on their initial therapies & challenges that arise in clinical trials vs in the real-world setting. #lymsm https://t.co/0GiE47rk0C (@OncLive)
9 months ago
Clinical • Real-world evidence • Real-world
9ms
Lots of great discussion on CLL and Lymphoma at the @_MDEducation meeting in La Jolla, San Diego. Meeting Co-chaired by Drs O’Brien and Flowers @ChrisRFlowersMD @DrSwami_Iyer @sparikhmd @Ryan_Fitzpatric (@NitinJainMD)
9 months ago
9ms
@GeorgeMikhaeel & I were involved in writing the lymphoma one (@becshakir)
9 months ago
9ms
Great discussions of local problems and opportunities with @DrMCanales and Armando Lopez Guillermo. Lymphoma leaders LATAM, 🇦🇷 and 🇺🇾 in the photo but amazing representation from other latam countries! (@laura_korin)
9 months ago
9ms
Congrats to @mshadman for receiving an endowed chair for his work in #cll and lymphoma! (@UjjaniC)
9 months ago
9ms
Discovering the fibroblastic reticular cell in the immune tumor microenvironment in lymphoma: https://t.co/kGtOTMSuQT Adam Yuh Lin & @ligordon highlight FRCs as a potential target to optimize immunotherapy for treatment of lymphoma; #Commentary Related: https://t.co/OswZjHSfaj (@jclinicalinvest)
9 months ago
9ms
Dr. Briehl is retiring? Best wishes to her! Privileged to count on her as lymphoma and administrative collaborator @UAZCancer (@DrDanPersky)
9 months ago
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login